

AHA HIGHLIGHTS

2025

 **MONDAY,
DECEMBER 8**

7:30 – 9:00 pm EST

Developed by:
 **CCRN**
Collaborative CME and Research Network

Program Overview:

This program covers key clinical trial findings and their implications from AHA 2025. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

VESALIUS – is there a role for PCSK9 inhibition in primary prevention or patients without events?

CORALreef – how effective is an oral PCSK9 inhibitor in patients with ASCVD or FH?

PolyHF – is a polypill the solution for patients with HFrEF?

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at AHA 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,
Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME & Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director, NSC Cardiology Clinical
Assistant Professor,
Medical College of Georgia at Augusta
University and Mercer University
Atlanta, GA



Register Now!

Visit: www.ccrnmd.com

For inquiries regarding this program, please contact
info@ccrnmd.com



This program was developed by CCRN